Screener
Oruka Therapeutics, Inc. ORKA Shares (Diluted)
Discontinued — last reported Q2 '25
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed August 11, 2025.
- Filed
- Aug 11, 2025
- Fiscal quarter
- Q2 FY2025
- Calendar quarter
- Q2 2025
- Accession
- 0001213900-25-074281
| Line item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Period from February 6, 2024 (Inception) to June 30, 2024 |
|---|---|---|---|---|
| Total other income (expense), net | 3,855 | (750) | 7,942 | (964) |
| Net loss | (24,574) | (22,243) | (45,573) | (29,320) |
| Net change in unrealized gains (losses) on marketable securities | (21) | — | 14 | — |
| Comprehensive loss | $(24,595) | $(22,243) | $(45,559) | $(29,320) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.46) | $(6.96) | $(0.85) | $(9.17) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(38.26) | — | $(71.23) | — |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 42,095,951 | 3,197,975 | 41,888,906 | 3,197,975 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 137,138 | — | 137,138 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s shares (diluted)?
- Oruka Therapeutics, Inc. (ORKA) reported shares (diluted) of 42.1M in Q2 2025.
- How has Oruka Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Oruka Therapeutics, Inc.'s shares (diluted) increased by 1216.3% year-over-year, from 3.2M to 42.1M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s shares (diluted)?
- Over 3 years (2021 to 2024), Oruka Therapeutics, Inc.'s shares (diluted) has grown at a -11.5% compound annual growth rate (CAGR), from 55.1M to 38.2M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Oruka Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude